Cardiac dysfunction in the trastuzumab clinical trials experience
- PMID: 11870163
- DOI: 10.1200/JCO.2002.20.5.1215
Cardiac dysfunction in the trastuzumab clinical trials experience
Abstract
Purpose: This study sought to estimate cardiac dysfunction (CD) risk for patients receiving trastuzumab; to characterize observed CD by severity, treatment, and clinical outcome; to assess effects of baseline clinical risk factors on CD; and to assess effects of cumulative doses of anthracyclines and trastuzumab on CD.
Patients and methods: A retrospective review of records for patients enrolled onto any of seven phase II and III trastuzumab clinical trials was performed. Predefined criteria were used for the diagnosis, and the New York Heart Association functional classification system was used to document CD severity. Product-limit estimates were used to summarize the cumulative anthracycline and trastuzumab doses at the time of CD onset.
Results: Patients treated with trastuzumab were found to be at an increased risk for CD. The incidence was greatest in patients receiving concomitant trastuzumab and anthracycline plus cyclophosphamide (27%). The risk was substantially lower in patients receiving paclitaxel and trastuzumab (13%) or trastuzumab alone (3% to 7%); however, most of these patients had received prior anthracycline therapy. CD was noted in 8% of patients receiving anthracycline plus cyclophosphamide and 1% receiving paclitaxel alone. Most trastuzumab-treated patients developing CD were symptomatic (75%), and most improved with standard treatment for congestive heart failure (79%).
Conclusion: Trastuzumab is associated with an increased risk of CD, which is greatest in patients receiving concurrent anthracyclines. In most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzumab.
Comment in
-
Cardiac dysfunction in the trastuzumab clinical experience.J Clin Oncol. 2002 Mar 1;20(5):1156-7. doi: 10.1200/JCO.2002.20.5.1156. J Clin Oncol. 2002. PMID: 11870153 No abstract available.
-
Cardiac dysfunction in clinical trials of trastuzumab.J Clin Oncol. 2002 Oct 1;20(19):4119; author reply 4120. doi: 10.1200/JCO.2002.99.124. J Clin Oncol. 2002. PMID: 12351610 No abstract available.
Similar articles
-
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.Clin Breast Cancer. 2004 Oct;5(4):293-8. doi: 10.3816/cbc.2004.n.033. Clin Breast Cancer. 2004. PMID: 15507176 Clinical Trial.
-
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.J Clin Oncol. 2005 Nov 1;23(31):7811-9. doi: 10.1200/JCO.2005.02.4091. J Clin Oncol. 2005. PMID: 16258083 Clinical Trial.
-
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.Br J Cancer. 2006 Apr 10;94(7):1016-20. doi: 10.1038/sj.bjc.6603060. Br J Cancer. 2006. PMID: 16570045 Free PMC article.
-
Clinical cardiac tolerability of trastuzumab.J Clin Oncol. 2004 Jan 15;22(2):322-9. doi: 10.1200/JCO.2004.01.120. J Clin Oncol. 2004. PMID: 14722042 Review.
-
Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.Oncology. 2001;61 Suppl 2:58-66. doi: 10.1159/000055403. Oncology. 2001. PMID: 11694789 Review.
Cited by
-
The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors.Front Oncol. 2015 Jan 13;4:384. doi: 10.3389/fonc.2014.00384. eCollection 2014. Front Oncol. 2015. PMID: 25629006 Free PMC article. Review.
-
Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.Clin Sci (Lond). 2020 Oct 16;134(19):2623-2643. doi: 10.1042/CS20200230. Clin Sci (Lond). 2020. PMID: 33063822 Free PMC article. Review.
-
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.Ann Oncol. 2013 Jul;24(7):1841-1847. doi: 10.1093/annonc/mdt121. Epub 2013 Apr 4. Ann Oncol. 2013. PMID: 23559151 Free PMC article. Clinical Trial.
-
Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?Future Cardiol. 2015 Jul;11(4):383-7. doi: 10.2217/FCA.15.48. Epub 2015 Aug 4. Future Cardiol. 2015. PMID: 26238689 Free PMC article. No abstract available.
-
Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network.Cancer. 2013 Feb 15;119(4):839-46. doi: 10.1002/cncr.27831. Epub 2012 Sep 25. Cancer. 2013. PMID: 23011924 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical